Inclusion Criteria:

   - Undergoing MVS for degenerative MR with (a) Moderate TR as determined by transthoracic
   2D echocardiography, or (b) Tricuspid annular dimension ≥ 40 mm (index: ≥21mm/M2 BSA)
   and trace/mild TR, determined by echocardiography.

   - Age ≥ 18 years

   - Able to sign Informed Consent and Release of Medical Information forms

Exclusion Criteria:

   - Functional MR

   - Evidence of sub-optimal fluid management (e.g., lack of diuretics, weight in excess of
   dry weight) in the opinion of the cardiology investigator

   - Structural / organic TV disease

   - Severe TV regurgitation as determined by preoperative transthoracic echocardiography
   (TTE)

   - Implanted pacemaker or defibrillator, where the leads cross the TV from the right
   atrium into the right ventricle

   - Concomitant cardiac surgery other than atrial fibrillation correction surgery (PVI,
   Maze, LAA closure), closure of PFO or ASD, or CABG

   - Cardiogenic shock at the time of randomization

   - STEMI requiring intervention within 7 days prior to randomization

   - Evidence of cirrhosis or hepatic synthetic failure

   - Severe, irreversible pulmonary hypertension in the judgment of the investigator

   - Pregnancy at the time of randomization

   - Therapy with an investigational intervention at the time of screening, or plan to
   enroll patient in additional investigational intervention study during participation
   in this trial

   - Any concurrent disease with life expectancy < 2 years

   - Unable or unwilling to provide informed consent

   - Unable or unwilling to comply with study follow up in the opinion of the investigator